2020
DOI: 10.1080/00325481.2020.1798162
|View full text |Cite
|
Sign up to set email alerts
|

Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?

Abstract: Oral semaglutide is the first US Food and Drug Administration-approved oral glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes (T2D). Prior articles within this supplement reviewed the PIONEER trial program, which demonstrated that oral semaglutide reduced glycated hemoglobin and body weight when given to patients with uncontrolled T2D on various background therapies, and had a safety profile consistent with subcutaneous GLP-1RAs. This article provides guidance on integrati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(9 citation statements)
references
References 61 publications
0
7
0
2
Order By: Relevance
“…Long-acting GLP-RAs are liraglutide (Victoza, Saxenda), once-weekly exenatide (Bydureon), dulaglutide (Trulicity), albiglutide (Eperzan, Tanzeum), semaglutide (Ozempic), and oral semaglutide (Rybelsus). GLP-1 RAs approved for use in T2DM treatment are summarized in Table 2 [ 33 , 34 , 35 ].…”
Section: Glp-1 Receptor Agonistsmentioning
confidence: 99%
“…Long-acting GLP-RAs are liraglutide (Victoza, Saxenda), once-weekly exenatide (Bydureon), dulaglutide (Trulicity), albiglutide (Eperzan, Tanzeum), semaglutide (Ozempic), and oral semaglutide (Rybelsus). GLP-1 RAs approved for use in T2DM treatment are summarized in Table 2 [ 33 , 34 , 35 ].…”
Section: Glp-1 Receptor Agonistsmentioning
confidence: 99%
“…The most frequent side effects were dose-related nausea and diarrhea [ 17 ]. Semaglutide should not be used in patients with history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as it increases the risk for thyroid c-cell carcinoma [ 48 ]. Contraindications are similar to liraglutide and the rest of the GLP-1 agonists since they have equal mechanisms of action.…”
Section: Resultsmentioning
confidence: 99%
“…However, it is important to note that the use of oral semaglutide is generally not recommended or requires special consideration for women who are pregnant or breastfeeding and for children with T2D. In addition, oral semaglutide is not indicated for people with type 1 diabetes or patients with diabetic ketoacidosis [ 45 ].…”
Section: Discussionmentioning
confidence: 99%